Loefflers syndrome differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 16: | Line 16: | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
|- | |- | ||
| colspan="2" rowspan=" | | colspan="2" rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms''' | ||
! colspan="2" rowspan=" | ! colspan="2" rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
|- | |- | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
|- | |- | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased Eosinophil | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased Eosinophil | ||
count | count | ||
Line 40: | Line 36: | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Transpulmonary | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Transpulmonary | ||
passage of larvae (Loffler's syndrome) | passage of larvae (Loffler's syndrome) | ||
| style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Cough | * Cough | ||
* Sputum production | * Sputum production | ||
* | |||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | |||
* Wheezing | * Wheezing | ||
* Fever | * Fever | ||
* Crackles | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 71: | Line 67: | ||
eosinophilia | eosinophilia | ||
| style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Cough | * Cough | ||
* Breathlessness | * Breathlessness | ||
* Fatigue | * Fatigue | ||
* | |||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | |||
* Fever. | * Fever. | ||
* Wheezing | |||
* Crackles | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* 40 to 70 percent (>3000/microL) plus elevated IgE levels ( >1000 units/mL) | * 40 to 70 percent (>3000/microL) plus elevated IgE levels ( >1000 units/mL) | ||
Line 99: | Line 95: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Allergic bronchopulmonary aspergillosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Allergic bronchopulmonary aspergillosis | ||
| style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* '''Repeated episodes of:''' | * '''Repeated episodes of:''' | ||
* Bronchial obstruction, inflammation | * Bronchial obstruction, inflammation | ||
Line 115: | Line 111: | ||
* Hemoptysis | * Hemoptysis | ||
* Wheezing | * Wheezing | ||
| | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Fever | |||
* Crackles | |||
* Wheezing | |||
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate | | style="background: #F5F5F5; padding: 5px;" |Mild to moderate | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 139: | Line 136: | ||
helminths | helminths | ||
| style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Depends on the organism for example: | * Depends on the organism for example: | ||
* Periorbital edema, myositis, and eosinophilia ('''Trichinellosis)''' | * Periorbital edema, myositis, and eosinophilia ('''Trichinellosis)''' | ||
| | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Depends on the organism for example: | |||
* Periorbital edema | |||
* Tenderness in muscles | |||
* Fever | |||
* ('''Trichinellosis)''' | |||
| style="background: #F5F5F5; padding: 5px;" |Mild to | | style="background: #F5F5F5; padding: 5px;" |Mild to | ||
moderate to | moderate to | ||
Line 167: | Line 167: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary parenchymal invasion | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary parenchymal invasion | ||
| | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Eosinophilia is prominent in the early stages of disease but minimal with established disease | * Eosinophilia is prominent in the early stages of disease but minimal with established disease | ||
Line 188: | Line 186: | ||
| rowspan="2" |Nonhelminthic infections | | rowspan="2" |Nonhelminthic infections | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis | ||
| rowspan="2" style="background: #F5F5F5; padding: 5px;" | | | colspan="2" rowspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure | * Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure | ||
| | | colspan="2" rowspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 203: | Line 199: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 215: | Line 208: | ||
|- | |- | ||
| colspan="2" |Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) | | colspan="2" |Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) | ||
| style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Sinusitis | * Sinusitis | ||
* Asthma, | * Asthma, | ||
* Skin, cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved. | * Skin, cardiovascular, gastrointestinal, renal, and neurologic systems may also be involved. | ||
| | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* <small>1500 cells/microL</small> | * <small>1500 cells/microL</small> | ||
Line 243: | Line 234: | ||
|- | |- | ||
| colspan="2" |Drug- and toxin-induced eosinophilic lung diseases | | colspan="2" |Drug- and toxin-induced eosinophilic lung diseases | ||
| style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Asymptomatic pulmonary infiltration with eosinophils | * Asymptomatic pulmonary infiltration with eosinophils | ||
* Chronic cough with or without dyspnea, fever, acute eosinophilic pneumonia, and | * Chronic cough with or without dyspnea, fever, acute eosinophilic pneumonia, and | ||
Line 251: | Line 242: | ||
* Enlarged lymph nodes | * Enlarged lymph nodes | ||
* History of initiation of a culprit medication two to six weeks prior to disease onset | * History of initiation of a culprit medication two to six weeks prior to disease onset | ||
| | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate | | style="background: #F5F5F5; padding: 5px;" |Mild to moderate | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 271: | Line 260: | ||
| | | | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic eosinophilic pneumonia | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Chronic eosinophilic pneumonia | ||
| style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Predominantly in women and nonsmokers | * Predominantly in women and nonsmokers | ||
* Following radiation therapy for breast cancer | * Following radiation therapy for breast cancer | ||
* Cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases | * Cough, fever, progressive breathlessness, weight loss, wheezing, and night sweats; asthma accompanies or precedes the illness in 50 percent of cases | ||
| | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* ≥40 percent | * ≥40 percent | ||
Line 301: | Line 288: | ||
| | | | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic acute eosinophilic pneumonia | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic acute eosinophilic pneumonia | ||
| style="background: #F5F5F5; padding: 5px;" | | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
* Acute respiratory failure in a previously healthy patient | * Acute respiratory failure in a previously healthy patient | ||
* | * | ||
Line 307: | Line 294: | ||
* Nonproductive cough | * Nonproductive cough | ||
* Dyspnea, | * Dyspnea, | ||
| | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* ≥25 percent | * ≥25 percent | ||
Line 345: | Line 330: | ||
| | | | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoidosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Sarcoidosis | ||
| | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate | | style="background: #F5F5F5; padding: 5px;" |Mild to moderate | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 359: | Line 342: | ||
| | | | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary Langerhans cell histiocytosis (Histiocytosis X) | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Pulmonary Langerhans cell histiocytosis (Histiocytosis X) | ||
| | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" |Mild to moderate | | style="background: #F5F5F5; padding: 5px;" |Mild to moderate | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 373: | Line 354: | ||
| | | | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic pulmonary fibrosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Idiopathic pulmonary fibrosis | ||
| | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" |<10 percent | | style="background: #F5F5F5; padding: 5px;" |<10 percent | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 387: | Line 366: | ||
| | | | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 7 | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 7 | ||
| | | colspan="2" style="background: #F5F5F5; padding: 5px;" | | ||
| colspan="2" style="background: #F5F5F5; padding: 5px;" | | |||
| | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 14:59, 11 June 2019
![](/images/1/16/Home_logo1.png)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Loeffler syndrome must be differentiated from other diseases that cause pulmonary eosinophilia, such as Churg-Strauss, drug and toxin-induced eosinophilic lung diseases, other helminthic and fungal infection related eosinophilic lung diseases, and nonhelminthic infections such as Coccidioidomycosis, and Mycobacterium tuberculosis.
Differentiating Loeffler syndrome from other pulmonary eosinophilia syndromes on the basis of etiology.
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | |||||||||||
Lab Findings | Imaging | Histopathology | ||||||||||
Increased Eosinophil
count |
Other lab findings | CXR | CT Scan | |||||||||
Helminthic
and fungal infection-related eosinophilic lung diseases |
Transpulmonary
passage of larvae (Loffler's syndrome) |
|
|
|
| |||||||
Tropical
pulmonary eosinophilia |
|
|
|
|
|
| ||||||
Allergic bronchopulmonary aspergillosis |
|
|
Mild to moderate |
|
|
|||||||
Heavy
hematogenous seeding with helminths |
|
|
Mild to
moderate to high |
|
|
| ||||||
Pulmonary parenchymal invasion |
|
|
|
|
| |||||||
Nonhelminthic infections | Coccidioidomycosis |
|
|
|||||||||
Mycobacterium tuberculosis | ||||||||||||
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) |
|
|
|
|
|
|||||||
Drug- and toxin-induced eosinophilic lung diseases |
|
Mild to moderate |
| |||||||||
Chronic eosinophilic pneumonia |
|
|
|
|
||||||||
Idiopathic acute eosinophilic pneumonia |
|
|
|
|
| |||||||
Diseases | Symptom 1 | Symptom 2 | Physical exam 1 | Physical exam 2 | Increased Eosinophil count
(High) |
Other lab findings | CXR | CT Scan | Histopathology | Gold standard | Additional findings | |
Sarcoidosis | Mild to moderate | |||||||||||
Pulmonary Langerhans cell histiocytosis (Histiocytosis X) | Mild to moderate | |||||||||||
Idiopathic pulmonary fibrosis | <10 percent | |||||||||||
Differential Diagnosis 7 |